This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sladek, C. D. Articles by Mangiapane, M. L. Search for Related Content PubMed PubMed Citation Articles by Sladek, C. D. Articles by Mangiapane, M. L.

Hypertension, Vol 12, 506-512, Copyright © 1988 by American Heart Association

ARTICLES

Attenuation of spontaneous hypertension in rats by a vasopressin antagonist

CD Sladek, ML Blair, C Sterling and ML Mangiapane
Department of Neurology, University of Rochester School of Medicine, New York.

Although abnormalities in the vasopressin system have been reported in spontaneously hypertensive rats (SHR), neither short-term nor long-term administration of the vasopressin antagonist d(CH2)5-Tyr(Me)arginine vasopressin (AVP), which selectively blocks the action of vasopressin on vascular (V1) receptors, altered the course of hypertension in SHR. In the current study, long-term administration of a different vasopressin antagonist, d(CH2)5-D-Tyr(Me)VAVP, to SHR and Wistar-Kyoto rats (WKY) from 4 to 12 weeks of age significantly attenuated the development of systolic hypertension in SHR (p less than 0.05) without altering blood pressure in normotensive WKY. The antagonist was delivered subcutaneously by osmopump at 0.1 microgram/hr. Systolic blood pressure was monitored twice weekly by tail plethysmography beginning at 5 weeks of age. In a second group of SHR, the drug infusion was continued until 18 weeks of age. In this group, the attenuation of systolic hypertension by the drug was extended and became more prominent (p less than 0.007). Resting mean arterial pressure measured by indwelling catheters in the conscious state at 18 weeks of age was significantly reduced in the antagonist-treated SHR (144 +/- 4 vs 157 +/- 4 mm Hg; p less than 0.05). Heart rate also was significantly reduced by the drug (351 +/- 6 vs 392 +/- 7 beats/min; p less than 0.001). Following measurement of mean arterial pressure in the rats at 18 weeks of age, the osmopumps were removed and systolic blood pressure, mean arterial pressure, and heart rate were observed until 22 weeks of age.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				T.-a. Koshimizu, Y. Nasa, A. Tanoue, R. Oikawa, Y. Kawahara, Y. Kiyono, T. Adachi, T. Tanaka, T. Kuwaki, T. Mori, et al. From the Cover: V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity PNAS, May 16, 2006; 103(20): 7807 - 7812. [Abstract] [Full Text] [PDF]

				S. W. Kim, W. Wang, T.-H. Kwon, M. A. Knepper, J. Frokiaer, and S. Nielsen Increased expression of ENaC subunits and increased apical targeting of AQP2 in the kidneys of spontaneously hypertensive rats Am J Physiol Renal Physiol, November 1, 2005; 289(5): F957 - F968. [Abstract] [Full Text] [PDF]

				O. B. Vagnes, F. H. Hansen, J. J. Feng, B. M. Iversen, and W. J. Arendshorst Enhanced Ca2+ response to AVP in preglomerular vessels from rats with genetic hypertension during different hydration states Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1249 - F1256. [Abstract] [Full Text] [PDF]

				C. Tahtaoui, M.-N. Balestre, P. Klotz, D. Rognan, C. Barberis, B. Mouillac, and M. Hibert Identification of the Binding Sites of the SR49059 Nonpeptide Antagonist into the V1a Vasopressin Receptor Using Sulfydryl-reactive Ligands and Cysteine Mutants as Chemical Sensors J. Biol. Chem., October 10, 2003; 278(41): 40010 - 40019. [Abstract] [Full Text] [PDF]

				H. E. De Wardener The Hypothalamus and Hypertension Physiol Rev, October 1, 2001; 81(4): 1599 - 1658. [Abstract] [Full Text] [PDF]

				M. Thibonnier, A. Kilani, M. Rahman, T. P. DiBlasi, K. Warner, M. C. Smith, A. F. Leenhardt, and R. Brouard Effects of the Nonpeptide V1 Vasopressin Receptor Antagonist SR49059 in Hypertensive Patients Hypertension, December 1, 1999; 34(6): 1293 - 1300. [Abstract] [Full Text] [PDF]

				J. Zicha and J. Kunes Ontogenetic Aspects of Hypertension Development: Analysis in the Rat Physiol Rev, October 1, 1999; 79(4): 1227 - 1282. [Abstract] [Full Text] [PDF]

				A. S. Budzikowski, F. Vahid-Ansari, G. S. Robertson, and F. H. H. Leenen Patterns of Neuronal Activation During Development of Sodium Sensitive Hypertension in SHR Hypertension, December 1, 1997; 30(6): 1572 - 1577. [Abstract] [Full Text]

				L. M. Burrell, P. A. Phillips, J. Risvanis, K. L. Aldred, A.-M. Hutchins, and C. I. Johnston Attenuation of Genetic Hypertension After Short-term Vasopressin V1A Receptor Antagonism Hypertension, November 1, 1995; 26(5): 828 - 834. [Abstract] [Full Text]